{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:13:26Z","timestamp":1794255206608,"version":"4.9.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transplant-associated thrombotic microangiopathy (TA-TMA), a complication of hematopoietic cell transplant (HCT), is associated with significant morbidity and mortality. The pathophysiology and overlap of TA-TMA with other posttransplant complications such as graft-versus-host disease (GVHD) is poorly understood. We retrospectively identified cases of TA-TMA among patients with grade 3\/4 gastrointestinal (GI) GVHD, reviewed intestinal biopsy specimens, and performed correlative testing of biomarkers associated with TA-TMA. TA-TMA was more common in patients with steroid-refractory GVHD compared with steroid-responsive GVHD (79.3% vs 42.1%; P = .001). Among patients surviving 100 days post-HCT, 1-year survival from day 100 was significantly better for patients who had not developed TA-TMA in the first 100 days (69.5% vs 36.7%; P &amp;lt; .001). Only 1 of 7 proposed TA-TMA histology criteria (mucosal hemorrhage) differed significantly based on GVHD steroid response. In multivariable modeling, steroid-refractory GVHD was a risk factor for development of TA-TMA (hazard ratio, 3.09; 95% confidence interval, 1.68-5.67; P &amp;lt; .001). There were no differences in complement activation at GVHD onset; however, 2 to 6 weeks later, patients with TA-TMA had higher levels of BBPlus and C5b-9, markers of alternative and terminal pathway activation (BBPlus: median, 600 vs 209.3 ng\/mL; P = .0045) (C5b-9: median, 425.9 vs 258.4 ng\/mL; P = .029). TA-TMA is associated with poor overall survival (OS) following HCT and may be detected early by histologic findings and may be differentiated from GVHD by measurement of alternative and terminal complement pathway activation. It is unknown whether treatment of TA-TMA will improve survival in steroid-refractory GVHD.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018020321","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T11:56:08Z","timestamp":1539690968000},"page":"2619-2628","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":65,"title":["Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD"],"prefix":"10.1182","volume":"2","author":[{"given":"Sarah A.","family":"Wall","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Yearsley","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Blower","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akwasi","family":"Agyeman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvathi","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangbin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwa","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bostic","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Brammer","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem","family":"William","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Choe","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice S.","family":"Mims","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Penza","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Devine","sequence":"additional","affiliation":[{"name":"Centers for International Blood and Marrow Transplantation Research, Minneapolis, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spero","family":"Cataland","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"issue":"3","key":"2020021108382000900_B1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"issue":"1","key":"2020021108382000900_B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.tp.0000297998.33418.7e","article-title":"Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study","volume":"85","author":"Siami","year":"2008","journal-title":"Transplantation"},{"issue":"11","key":"2020021108382000900_B3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1083-8791(03)00243-X","article-title":"Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation","volume":"9","author":"El-Seisi","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020021108382000900_B4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020021108382000900_B5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020021108382000900_B6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"issue":"8","key":"2020021108382000900_B7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"issue":"9","key":"2020021108382000900_B8","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/j.1537-2995.2009.02217.x","article-title":"Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria","volume":"49","author":"Kennedy","year":"2009","journal-title":"Transfusion"},{"issue":"3","key":"2020021108382000900_B9","doi-asserted-by":"crossref","first-page":"e2010033","DOI":"10.4084\/mjhid.2010.033","article-title":"Thrombotic microangiopathy in haematopoietic cell transplantation: an update","volume":"2","author":"Stavrou","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"2020021108382000900_B10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/bmt.2016.253","article-title":"Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?","volume":"52","author":"Dhakal","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020021108382000900_B11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1076029615598221","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"22","author":"Elsallabi","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"24","key":"2020021108382000900_B12","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2020021108382000900_B13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","article-title":"Complement activation in thrombotic thrombocytopenic purpura","volume":"10","author":"R\u00e9ti","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"23","key":"2020021108382000900_B14","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2020021108382000900_B15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2020021108382000900_B16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.transci.2016.04.007","article-title":"New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"54","author":"Jodele","year":"2016","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"2020021108382000900_B17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","author":"Vasu","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020021108382000900_B18","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020021108382000900_B19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in transplant-associated thrombotic microangiopathy","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"issue":"22","key":"2020021108382000900_B20","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"2020021108382000900_B21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020021108382000900_B22","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2352-3026(14)00035-0","article-title":"A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study","volume":"2","author":"Levine","year":"2015","journal-title":"Lancet Haematol"},{"issue":"6","key":"2020021108382000900_B23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1213299","article-title":"ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death","volume":"369","author":"Vander Lugt","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2020021108382000900_B24","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020021108382000900_B25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/bmt.2015.247","article-title":"The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD","volume":"51","author":"Nadeau","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2020021108382000900_B26","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.bbmt.2014.05.031","article-title":"Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease","volume":"20","author":"Meunier","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020021108382000900_B27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.bbmt.2015.08.039","article-title":"Combination therapy with inolimomab and etanercept for severe steroid-refractory acute graft-versus-host disease","volume":"22","author":"van Groningen","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020021108382000900_B28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbmt.2012.09.018","article-title":"Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment","volume":"19","author":"Dietrich","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021108382000900_B29","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood-2011-02-334821","article-title":"Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system","volume":"118","author":"Luft","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2020021108382000900_B30","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bbmt.2014.05.002","article-title":"Endothelial dysfunction and altered mechanical and structural properties of resistance arteries in a murine model of graft-versus-host disease","volume":"20","author":"Schmid","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020021108382000900_B31","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3727\/096368916X691646","article-title":"Vascular alterations in a murine model of acute graft-versus-host disease are associated with decreased serum levels of adiponectin and an increased activity and vascular expression of indoleamine 2,3-dioxygenase","volume":"25","author":"Schmid","year":"2016","journal-title":"Cell Transplant"},{"issue":"10","key":"2020021108382000900_B32","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/bmt.2017.119","article-title":"Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD","volume":"52","author":"Zeisbrich","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2020021108382000900_B33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbmt.2018.01.009","article-title":"Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic microangiopathy after stem cell transplantation","volume":"24","author":"Horv\u00e1th","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020021108382000900_B34","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood-2017-05-782870","article-title":"Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD","volume":"130","author":"Gloude","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020021108382000900_B35","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1700185","article-title":"ST2 and endothelial injury as a link between GVHD and microangiopathy","volume":"376","author":"Rotz","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2020021108382000900_B36","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.bbmt.2015.06.016","article-title":"Histologic features of intestinal thrombotic microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation","volume":"21","author":"El-Bietar","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020021108382000900_B37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1309\/AJCPXPD7ZQXNTIAL","article-title":"Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers","volume":"143","author":"Yang","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"2020021108382000900_B38","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/blood-2005-12-4851","article-title":"Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin","volume":"107","author":"Van Lint","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2020021108382000900_B39","first-page":"2288","article-title":"Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation","volume":"92","author":"Van Lint","year":"1998","journal-title":"Blood"},{"key":"2020021108382000900_B40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trim.2017.06.004","article-title":"Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation","volume":"43-44","author":"Nomura","year":"2017","journal-title":"Transpl Immunol"},{"issue":"8","key":"2020021108382000900_B41","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bbmt.2017.04.029","article-title":"Predictive value of clinical findings and plasma biomarkers after fourteen days of prednisone treatment for acute graft-versus-host disease","volume":"23","author":"McDonald","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020021108382000900_B42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood-2015-03-636753","article-title":"Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment","volume":"126","author":"McDonald","year":"2015","journal-title":"Blood"},{"issue":"308","key":"2020021108382000900_B43","doi-asserted-by":"crossref","first-page":"308ra160","DOI":"10.1126\/scitranslmed.aab0166","article-title":"ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease","volume":"7","author":"Zhang","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"2020021108382000900_B44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bmt.2017.236","article-title":"Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402","volume":"53","author":"Turcotte","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020021108382000900_B45","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ard.2009.119321","article-title":"The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis","volume":"69","author":"Manetti","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2020021108382000900_B46","doi-asserted-by":"crossref","first-page":"e0178939","DOI":"10.1371\/journal.pone.0178939","article-title":"IL-33 and ST2 levels in chronic kidney disease: associations with inflammation, vascular abnormalities, cardiovascular events, and survival","volume":"12","author":"Gungor","year":"2017","journal-title":"PLoS One"},{"issue":"14","key":"2020021108382000900_B47","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2009-05-219402","article-title":"Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease","volume":"114","author":"Yi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020021108382000900_B48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/01.CIR.96.1.326","article-title":"Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway","volume":"96","author":"Collard","year":"1997","journal-title":"Circulation"},{"issue":"12","key":"2020021108382000900_B49","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1699-0463.1998.tb00271.x","article-title":"Complement activation and regulator expression after anoxic injury of human endothelial cells","volume":"106","author":"V\u00e4kev\u00e4","year":"1998","journal-title":"APMIS"},{"issue":"10","key":"2020021108382000900_B50","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.humpath.2013.02.023","article-title":"CD123 is a useful immunohistochemical marker to facilitate diagnosis of acute graft-versus-host disease in colon","volume":"44","author":"Lin","year":"2013","journal-title":"Hum Pathol"},{"issue":"suppl 2","key":"2020021108382000900_B51","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1016\/j.bbmt.2010.12.537","article-title":"The role of complement system in the pathogenesis of graft versus host disease","volume":"17","author":"Cherry","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020021108382000900_B52","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00277-017-3092-9","article-title":"Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"96","author":"Qi","year":"2017","journal-title":"Ann Hematol"},{"issue":"9674","key":"2020021108382000900_B53","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"2020021108382000900_B54","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/bmt.2010.112","article-title":"Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated","volume":"46","author":"Poutsiaka","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2020021108382000900_B55","doi-asserted-by":"crossref","first-page":"e26821","DOI":"10.1002\/pbc.26821","article-title":"Early blood stream infection following allogeneic hematopoietic stem cell transplantation is a risk factor for acute grade III-IV GVHD in children and adolescents","volume":"65","author":"Sano","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2020021108382000900_B56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ajh.20648","article-title":"Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation","volume":"81","author":"Nakamae","year":"2006","journal-title":"Am J Hematol"},{"issue":"12","key":"2020021108382000900_B57","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/20\/2619\/1629583\/advances020321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/20\/2619\/1629583\/advances020321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:10:44Z","timestamp":1581412244000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/20\/2619\/16112\/Complementmediated-thrombotic-microangiopathy-as-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":57,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2018,10,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018020321","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]}}}